Clinical trial
Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With…
NCT00103974 · Bayhill Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00103974 |
|---|---|
| Title | Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis |
| Official title | A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis |
| Lead sponsor | Bayhill Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Biological |
| Interventions | BHT-3009-01 |
| Enrollment | 30 |
| Start date | Jul 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Feb 18, 2005 |
| Last update posted | Apr 7, 2008 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: